Avalon Investment & Advisory Supernus Pharmaceuticals, Inc. Transaction History

Avalon Investment & Advisory

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$30.84 - $49.51 $2.09 Million - $3.36 Million	-67,899 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $205,984 - $272,797	4,824 Added 7.65%	67,899 $3.42 Million
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $1.14 Million - $1.54 Million	25,786 Added 69.15%	63,075 $3.78 Million
Q1 2018 Jun 26, 2018	BUY	$37.15 - $46.9 $130,953 - $165,322	3,525 Added 10.44%	37,289 $1.71 Million
Q1 2018 Jun 22, 2018	SELL	$37.15 - $46.9 $131,139 - $165,557	-3,530 Reduced 9.47%	33,764 $1.35 Million
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $131,139 - $165,557	3,530 Added 10.45%	37,294 $1.71 Million
Q4 2017 Jun 22, 2018	SELL	$36.4 - $42.6 $4,586 - $5,367	-126 Reduced 0.37%	33,764 $1.35 Million
Q4 2017 Feb 14, 2018	BUY	$36.4 - $42.6 $45,791 - $53,590	1,258 Added 3.86%	33,890 $1.35 Million
Q3 2017 Nov 14, 2017	SELL	$36.75 - $49.65 $9,077 - $12,263	-247 Reduced 0.75%	32,632 $1.31 Million
Q2 2017 Aug 14, 2017	BUY	N/A	32,879	32,879 $1.42 Million

281

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Avalon Investment & Advisory, based on Form 13F filings with the SEC.

Stay updated on Avalon Investment & Advisory with notifications on news.